In addition, adjunctive therapy with pitavastatin to telmisartan greatly attenuated the activity of the TGF-b/smad3 and NF-kB pathways and then inhibited renal fibrosis and inflammation leading to renoprotection [59]. This evidence concerns the gene NFKB1 and renal fibrosis.